The 10th Asia-Pacific AIDS and Co-Infections Conference (APACC) was successfully hosted in Tokyo, Japan from June 12 to 14, 2025. Aidea Pharma made a high-profile presence at the conference with a featured oral presentation and multiple poster sessions highlighting its breakthrough, the first domestically developed oral fixed-dose combination anti-HIV innovative drug, Ainuomiti Tablets. As a leading innovator in HIV treatment in China, Aidea Pharma shared the stage with global pharmaceutical leaders such as GlaxoSmithKline and Gilead, infusing new vitality into the fight against HIV/AIDS across the Asia-Pacific region.

Professor Fujie Zhang from Beijing Ditan Hospital, Capital Medical University, delivered a highly anticipated oral presentation focusing on treatment options and health management for young PWH. The presentation highlighted key research findings of the Ainuomiti Tablets (ANV/3TC/TDF) , sparking lively discussions among attending experts.

Focus on Asia-Pacific Youth: Growth Concerns Under Low Prevalence, Balancing Efficacy and Long-Term Health

Globally, the population of young people living with HIV (PWH) was approximately 420,000 in 2019. Most countries and regions in the Asia-Pacific, including China, South Korea, Japan, Vietnam, and the Philippines, are facing the challenge of a continuously increasing HIV incidence. Meanwhile, previous studies have shown that young PWH face a higher risk of premature atherosclerotic cardiovascular disease (ASCVD) compared to their non-infected peers, underscoring the importance of prioritizing long-term cardiometabolic safety of antiretroviral therapy (ART) while ensuring efficacy.

Ainuomiti Tablets Research: RACER & SPRINT Studies

Both the RACER and SPRINT studies are prospective, multicenter, randomized, active-controlled trials. The RACER study compared the the novel NNRTI Ainuovirine (ANV)-based regimen with the Efavirenz (EFV)-based regimen in treatment-naïve PWH, while the SPRINT study evaluated the efficacy of switching virologically suppressed PWH to the Ainuomiti Tablets regimen.

This presentation primarily conducted a pooled analysis of data from young and middle-aged subgroups (18–25 years old) in these two studies, aiming to systematically evaluate the efficacy, safety, and cardiometabolic characteristics of the Ainuomiti Tablets (ANV/3TC/TDF) regimen in young PWH.

Outstanding Results: Confirmed Efficacy and Prominent Cardiovascular-Metabolic Benefits

The analysis showed that the ANV-based regimen demonstrated effective virologic suppression, immune reconstitution, and overall good tolerability in young PWH, with stable and reliable efficacy compared to other treatment regimens (NNRTI or INSTI) in both treatment-naïve and treatment-experienced switch PWH.

Furthermore, the study showed significant cardiovascular and metabolic benefits in young PWH. Compared with the control regimen, the ANV-based regimen was associated with significantly fewer neuropsychiatric symptoms and smaller weight gain. Additionally, participants in the ANV-based group had lower lipid profiles, significantly reducing the incidence of lipid abnormalities related to ASCVD risk. Given the rising HIV infection rate and increased risk of premature cardiovascular disease among youth in the Asia-Pacific region, the ANV-based regimen more precisely meets the special needs and long-term health management goals of young PWH.

In addition to the oral presentation, multiple results were presented in poster form, covering treatment-naïve/experienced PWH, female, middle-aged, and PWH with co-existing sexually transmitted infections. The 96-week data from the SPRINT study showed that the ANV-based regimen maintained a high virological suppression rate in both treatment-naïve and experienced PWH (the proportion of RNA ≥50 copies/mL at 96 weeks was only 3.4%), non-inferior to the control regimen (EVG/c/3TC/TAF), and performed equally well in female and middle-aged PWH. Meanwhile, the ANV-based regimen showed significant benefits in metabolism, such as lipid improvement, weight management, and uric acid control, compared with the control group. It also significantly reduced the risk of neuropsychiatric adverse events and metabolic comorbidities such as fatty liver and hyperuricemia, demonstrating prominent safety benefits.

Domestic Innovative Drug Empowers Long-Term Management of Young PWH

With the successful host of APACC 2025, Ainuomiti Tablets has once again been thrust into the spotlight. The ANV-based regimen (such as Ainuomiti Tablets), with its solid efficacy foundation and unique cardiometabolic safety benefits—particularly in weight management, neuropsychiatric side effects, and lipid control—not only brings a more comprehensive, friendly, and future-oriented treatment option to the growing population of young PWH in the Asia-Pacific region but also, as an innovative, new-generation NNRTI developed in China, provides another comprehensive and long-term management solution for PWH.